Research programme: CYC102 cell cycle peptidomimetics - Cyclacel Pharmaceuticals
Alternative Names: CYC102Latest Information Update: 17 Feb 2010
At a glance
- Originator Cyclacel Pharmaceuticals
- Class Antineoplastics; Peptides
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 28 Mar 2006 Xcyte Therapies has merged with Cyclacel to form Cyclacel Pharmaceuticals
- 03 Mar 2006 This programme is still in active development
- 16 Oct 2001 CYC 102 is available for licensing (http://www.cyclacel.com)